Akari Therapeutics, Plc (AKTX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
AKTX Revenue Analysis (2013–2024)
As of March 2, 2026, Akari Therapeutics, Plc (AKTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, AKTX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and ABVX (+125.1% YoY). Compare AKTX vs ARGX →
Peer Comparison
Compare AKTX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AKTXCurrent | $0 | - | - | - | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-21,643,000 | - |
| 2023 | $0 | - | $0 | - | $-16,806,000 | - |
| 2022 | $0 | - | $0 | - | $-23,088,000 | - |
| 2021 | $0 | - | $0 | - | $-17,214,136 | - |
| 2020 | $0 | - | $0 | - | $-17,980,974 | - |
| 2019 | $0 | - | $-19,205 | - | $-24,870,333 | - |
| 2018 | $0 | - | $-35,848 | - | $-19,991,534 | - |
| 2017 | $0 | - | $-42,400 | - | $-34,959,189 | - |
| 2016 | $0 | - | $-39,772 | - | $-27,246,558 | - |
| 2015 | $0 | - | $-10,159 | - | $-30,584,570 | - |
See AKTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AKTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AKTX vs AGIO
See how AKTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AKTX's revenue growth accelerating or slowing?
AKTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is AKTX's long-term revenue growth rate?
Akari Therapeutics, Plc's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is AKTX's revenue distributed by segment?
AKTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.